Stem cells for luminal, fistulizing, and perianal inflammatory bowel disease: a comprehensive updated review of the literature

Erica P Turse, Francis E Dailey, Maliha Naseer, Edward K Partyka, Jack D Bragg, Veysel Tahan Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Missouri Health Center, Columbia, MO 65212, USA Abstract: Much research has been performed over the last decade on...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Turse EP, Dailey FE, Naseer M, Partyka EK, Bragg JD, Tahan V
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://doaj.org/article/d33b27eea4f94deab00cbfeda5a6fd52
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Erica P Turse, Francis E Dailey, Maliha Naseer, Edward K Partyka, Jack D Bragg, Veysel Tahan Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Missouri Health Center, Columbia, MO 65212, USA Abstract: Much research has been performed over the last decade on stem cell therapy as treatment for patients with inflammatory bowel disease. Hematopoietic and mesenchymal stem cells, both allogeneic (from someone else) and autologous (from own patient), have been studied with safe and efficacious results in the majority of patients treated for luminal, perianal, and/or fistulizing disease. Here in this review, we highlight all human trials that have been conducted utilizing stem cell therapy treatment in patients with inflammatory bowel disease. Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, mesenchymal, hematopoietic, autologous, allogeneic, therapy, treatment